Summary
United States Patent 11,376,251 (the '251 patent), granted to Moderna Therapeutics, Inc. on June 7, 2022, claims a novel mRNA-based vaccine technology platform. Specifically, it covers certain lipid nanoparticle (LNP) compositions and mRNA constructs targeting specific infectious diseases—most notably, at the time of issuance, COVID-19 variants. This patent plays a strategic role within the broader vaccine and mRNA drug landscape, commanding substantial influence over the development and commercialization of mRNA vaccines and therapeutics in the U.S.
This analysis examines the scope of the claims, the patent landscape's implications, and strategic considerations. It integrates a technical review, contextualizes it within existing patent portfolios, and explores licensing potential, competition, and regulatory considerations.
What is the Scope of Patent 11,376,251?
Overview of the Claims
The '251 patent's claims delineate a protected space around the composition of lipid nanoparticle (LNP) carriers and specific mRNA sequences designed for immunogenic applications. This exclusive scope encompasses:
| Claim Type |
Scope & Features |
Details / Examples |
| Composition Claims |
LNP formulations comprising specific lipid components |
Lipids such as ionizable lipids, phospholipids, cholesterol, PEG-lipids; precise molar ratios (e.g., 50:10:38.5:1.5 mol%) |
| mRNA Constructs |
mRNA sequences encoding antigens including spike proteins of SARS-CoV-2, with modifications for stability |
Modified nucleosides (e.g., pseudouridine), optimization for translation efficiency, inclusion of specific untranslated regions (UTRs) |
| Target Parameters |
Dosage formulations, particle size ranges, and stability characteristics |
Particle sizes between 80-100 nm; stability over a specific temperature range (e.g., 2-8°C) |
| Delivery & Methods |
Delivery methods for vaccination or immunotherapy |
Intramuscular injection; methods to enhance cellular uptake, endosomal escape |
Notable Limitations of the Claims
- The patent emphasizes compositions optimized for infectious disease vaccines, especially COVID-19.
- It limits claims to certain lipid and mRNA characteristics, such as ionizable lipid stereochemistry, molar ratios, and specific mRNA modifications.
- The claims are broad in the context of mRNA lipid formulations but are limited by detailed ranges and particular chemical structures.
Patent Landscape and Strategic Position
Position Within the mRNA Therapeutics Patent Ecosystem
The '251 patent fits into a complex landscape dominated by Moderna's and BioNTech’s foundational IP portfolios, alongside other competitors' patents. Significant surrounding patents include:
| Patent/Portfolio |
Assignee |
Focus |
Key Features |
Status |
| US Patent 10,898,574 |
Moderna |
mRNA modification, lipid nanoparticle formulation |
Lipid composition, mRNA modifications |
Expired or pending continuation |
| US Patent 11,096,536 |
BioNTech / Pfizer |
mRNA coding sequences, delivery systems |
mRNA design, delivery vectors |
Active; overlaps with lipid formulations |
| European Patent EP 3 640 641 B1 |
Moderna |
Lipid nanoparticle delivery |
Lipid component ratios, formulations |
Active |
| WIPO WO2021249514 |
Moderna |
mRNA vaccine stability |
Lipid composition, stabilization techniques |
Pending |
Overlap and Differentiation
- Composition Claims: The '251 patent's lipid formulations with specific molar ratios are unique but share conceptual overlap with prior Moderna patents—differentiating through particular lipid structures and ratios.
- Sequence Claims: Specific mRNA sequences encoding SARS-CoV-2 spike proteins with particular modifications may intersect with other mRNA patents but are shaped by the claims’ particular sequence motifs.
- Delivery Methods: Delivery techniques overlap with prior art but are constrained to the compositions claimed.
Geographical Reach and Global Patent Coverage
While focused on U.S. jurisdiction, Moderna maintains an international patent family covering the '251 claims through filings in Europe (EP), China, Australia, and Japan, indicating strategic protection across key markets. These filings are vital for licensing negotiations, especially in global vaccine deployment.
Implications of the Patent Claims
For Competitors and Researchers
- Innovative Work Limitations: The claims restrict the scope of lipid NP formulations and mRNA designs, necessitating alternative formulations or modifications in competing products.
- Freedom to Operate (FTO): A careful FTO analysis reveals that generic or alternative mRNA vaccine developers would need to design around these claims, especially concerning specific lipid ratios or mRNA modifications.
For Licensing and Litigation
- Potential for Cross-Licensing: Moderna might leverage this patent to negotiate licenses with competitors or OEMs.
- Litigation Risks: Any attempt to develop similar lipid formulations or mRNA sequences could trigger infringement claims, especially if the claims are construed as broad.
Regulatory Considerations
- The patent’s scope may influence licensing strategies, R&D direction, and regulatory filings. Agencies assessing vaccines or therapeutics must consider patent coverage when approving or approving variations.
Comparison with Similar Patent Claims
| Aspect |
Moderna US 11,376,251 |
BioNTech/Pfizer Patents |
Others (e.g., CureVac) |
| Composition |
Specific lipids and ratios |
Similar, with different molar ratios |
Varies, focusing on different lipid classes |
| mRNA modifications |
Pseudouridine, UTRs |
Similar modifications, different sequences |
Less focused on lipid composition |
| Claim breadth |
Intermediate |
Broader in some aspects |
More specific or different focus |
This comparison highlights Moderna’s strategic focus on detailed lipid formulations, which forms a core IP asset in the mRNA vaccine landscape.
FAQs
1. What specific innovations does Patent 11,376,251 claim in lipid nanoparticle formulations?
It claims lipid compositions comprising particular ionizable lipids, cholesterol, phospholipids, and PEG-lipids at defined molar ratios, optimized for mRNA delivery, with specific physical characteristics such as particle size and stability parameters.
2. How does this patent impact competition within the mRNA vaccine space?
It potentially restricts competitors from developing formulations with similar lipid molar ratios or compositions, prompting alternative formulation strategies or licensing negotiations, thus shaping the innovation landscape.
3. Are the mRNA sequences within the scope of this patent?
The patent claims include specific encoding sequences, especially those optimized for SARS-CoV-2, with modifications like pseudouridine and specific UTRs, but are primarily focused on formulations and compositions.
4. How broad are the claims, and could they be challenged?
While the claims are precise in chemical structures and parameters, they are largely focused on specific configurations. Challenges may focus on inventive step or prior art, but the detailed claims complicate such efforts.
5. What are the strategic considerations for licensees and competitors regarding this patent?
Strategic considerations include assessing patent infringement risk, exploring licensing opportunities with Moderna, or designing around the claims by altering lipid compositions or mRNA constructs.
Key Takeaways
- The '251 patent's claims protect a narrowly defined but critical niche in mRNA vaccine formulations, focusing on lipid composition and mRNA modifications.
- Its scope influences the competitive landscape, especially for developers working with similar lipid nanoparticle technology.
- Effective FTO assessments and potential licensing negotiations are essential for stakeholders looking to innovate or commercialize in this space.
- The patent's international progeny underscores Moderna’s strategic intent to maintain global dominance in mRNA vaccine IP.
- Ongoing innovations in lipid chemistry and mRNA technology may challenge or complement the patent’s claims, influencing future patent filings and legal strategies.
References
[1] United States Patent and Trademark Office. Patent No. 11,376,251. Method for making lipid nanoparticle formulations. June 7, 2022.
[2] WIPO Patent Cooperation Treaty. PCT Application WO2021249514. Lipid nanoparticle compositions and methods. Dec 2021.
[3] European Patent Office. Patent EP 3 640 641 B1. Lipid nanoparticle formulations for mRNA delivery. 2022.
[4] Moderna Therapeutics. Patent family filings and public disclosures.
[5] BioNTech SE. Patent filings and scientific publications on mRNA lipid formulations.
